Pharmaxis Limited (ASX:PXS) has seen an improvement in its annual result because of reduced operating expenses.
The loss is 1 per cent smaller than the previous year. The net loss was $45.7 million, down from $46.3 million the year before. Revenue fell 17 per cent.
The pharmacist, which develops treatments for respiratory conditions will pay no final dividend.